Phosphoric Acid → HCID 86621457, 화합물
반응식
[C:1]1([C:7]2[S:11][C:10]([O:12][C@@H:13]3[CH:20]4[CH2:21][N:16]5[CH2:17][CH:18]([CH2:22][CH:14]3[CH2:15]5)[CH2:19]4)=[N:9][N:8]=2)[CH:6]=[CH:5][CH:4]=[CH:3][CH:2]=1.[P:23](=[O:27])([OH:26])([OH:25])[OH:24]>CO>[P:23]([OH:27])([OH:26])([OH:25])=[O:24].[C:1]1([C:7]2[S:11][C:10]([O:12][C@@H:13]3[CH:20]4[CH2:21][N:16]5[CH2:17][CH:18]([CH2:22][CH:14]3[CH2:15]5)[CH2:19]4)=[N:9][N:8]=2)[CH:2]=[CH:3][CH:4]=[CH:5][CH:6]=1참가 물질
4
실험 절차
(4s)-4-(5-Phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane free base (20 mg, 0.064 mmol) was dissolved in 1.0 mL of methanol. Meanwhile, 5 μL of 85% phosphoric acid (0.073 mmol) was diluted with 245 μL methanol. The phosphoric acid solution was then added dropwise to the (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane free base solution while stirring. The vial was removed from the stir plate after the addition. The dihydrogen phosphate anhydrate crystallized upon standing.